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Abstract
Background: Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for
angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without
correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that ‘‘true’’ circulating (c)VEGF levels in
most cancer patients are low and unrelated to cancer load or tumour angiogenesis.
Methodology: We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma,
and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with
renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in
controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels
were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during
blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10
6, non-RCC: 6.2 IU/
10
6 platelets, p=0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC
vs. non-RCC, p,0.0001), and not related to platelet VEGF concentration.
Conclusions: Our findings suggest that ‘‘true’’ freely cVEGF levels are not elevated in the majority of cancer patients.
Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets,
which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is
characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation
may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in
RCC compared to other forms of cancer.
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Introduction
Vascular endothelial growth factor (VEGF) is the prime
regulator of angiogenesis in tumours [1–3]. It is released by
cancer cells, hypoxic cells and activated platelets and leukocytes
[4–8]. The target cells of VEGF are primarily vascular endothelial
cells on which it has powerful mitogenic effects via high affinity
receptors Flt-1 and KDR/Flk-1 [9,10]. As VEGF is a soluble
diffusible peptide secreted by tumours, its levels in the circulation
were proposed to reflect the angiogenic activity of malignancies.
Hence in the past years, circulating levels of VEGF and other
angiogenic factors have been widely studied as surrogate markers
of angiogenic activity and prognosis in cancer patients, for
monitoring treatment response and for detection of early relapse
[11].
For this purpose, VEGF levels determined in serum or plasma
were used. However, serum contains high levels of VEGF due to
release by activated platelets during clotting [5–7]. Therefore,
VEGF levels in serum, which correlate closely with blood platelet
count [12], do not reflect the actual circulating concentration of
VEGF in vivo. In citrate or EDTA plasma, where less platelet
activation and subsequent VEGF release is expected than in
serum, VEGF levels were found to be still higher in cancer patients
than in controls and this was interpreted as a reflection of higher
levels of VEGF in the circulation and higher angiogenic activity
[13–15]. But also by these authors artificial release of VEGF from
platelets, or altered behaviour of platelets in cancer patients, was
not excluded as a source of increased VEGF levels in the plasma
samples.
The aim of this study was to investigate the possibility that
artificial VEGF release by platelets is the main source of VEGF in
plasma samples, and that circulating levels of VEGF in cancer
patients are low and even unrelated to cancer load or angiogenic
activity. For this purpose, we determined plasma levels of VEGF
with or without inhibition of platelet activation, and quantified
VEGF release from platelets in vitro, in control persons without
cancer, patients with metastatic non-renal cell carcinoma patients
and patients with metastatic renal cell carcinoma.
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Patients and volunteers
We obtained venous blood from 16 healthy volunteers
(Controls) and from 30 cancer patients, separated in two patients
groups: 18 patients with metastatic non-RCC (Non-RCC) and 12
patients with metastatic RCC (RCC). RCC was characterized by
high intra-tumour VEGF production by mutations in the von
Hippel-Lindau tumour suppressor gene with consequent unlimited
activity of the hypoxia inducible factor 1a (HIF1a) causing high
VEGF transcription [16–20].
We investigated VEGF levels in citrate plasma, PECT plasma
and in platelets. The characteristics of volunteers and patients are
as follows: healthy controls (Controls) median age, 53 [48–60];
cancer patients (Non-RCC-group); median age, 62 [57–72]; with
cancer of the pancreas (7), cholangio (3), Papilli of Vater (2),
esophagus (1), colon and rectum (2), melanoma (1), ovary(1), breast
(1). RCC (RCC-group) median age, 60 [56–65]; with the following
prognostic groups: 5 poor-risk, 5 intermediate risk and 2
favourable risk, according to Motzer [21]. All cancer patients
had metastatic disease. To discriminate between in vivo platelet
activation and artificial in vitro platelet activation during plasma
harvest, b-TG and PF4 were measured in all samples. Blood
samples used in this study were derived from RCC patients
included in the BAYER 43-9006 study (approved by the Medical
Ethics Committee (METC 05-262), Academic Medical Center,
university of Amsterdam), non-RCC patients not included in a
specific study, and volunteers. From all volunteers and patients
separate written informed consent was obtained for blood sample
harvest and angiogenesis biomarker determinations.
Plasma preparations
For comparison with standard citrate plasma collection, we
employed a method to (maximally) avoid artificial ex vivo platelet
activation by blood collection without tourniquet, and harvest in a
medium containing a mixture of anticoagulants to which pro-
staglandin E1 and theophylline was added (PECT medium). In
addition, we used an important tool to discriminate between in
vivo platelet activation and artificial in vitro platelet activation, i.e.
measurements of b-thromboglobulin (b-TG) and platelet factor 4
(PF4) levels. Collection in PECT plasma and concomitant use of
markers of platelet activation should provide an accurate
estimation of the circulating levels of VEGF in vivo.
From each patient or volunteer venous blood was taken with a
microperfuser (diameter 1 mm, Microflex, Vycon, Ecouen,
France) and divided into different tubes. Plastic (polypropylene)
blood collection tubes were filled with 400 mL of a solution
containing: prostaglandin E1 (94 nM), Na2CO3 (0.63 mM),
EDTA (90 mM) and theophylin (10 mM) (PECT-medium). Blood
samples (4 ml) were collected in these PECT tubes in an open
system, drop by drop without using a tourniquet to (maximally)
avoid platelet activation ex vivo. Blood collected in the PECT
tubes was immediately placed on ice (in contrast to the citrate and
EDTA blood samples which were kept at room temperature).
Platelet-depleted PECT plasma was prepared by spinning for
60 min at 1700 g at 4uC within 1 hour after collection.
Blood was also collected in tubes filled with citrate and in tubes
filled with EDTA using a tourniquet (Becton Dickinson Vacutai-
ners Systems, Breda, The Netherlands). The citrate blood samples
were centrifuged within 30 minutes for 15 minutes at 1000 g to
obtain plasma. EDTA blood drawn in the same manner was used
to measure total number of platelets. To measure VEGF, PF4 and
b-TG within the platelets, EDTA blood was used in which
platelets were destroyed by a combination of Triton (2% Triton
X-100), sonication during 15 seconds on ice (microtip, Branson,
amplitude 50%) and centrifuging during 5 minutes at 14.000 rpm
in a micro-centrifuge. Platelet-depleted PECT plasma was used to
measure VEGF, PF4 and b-TG levels. Citrate plasma was used to
measure VEGF and PF4 levels.
Measurements of platelet activation markers and VEGF
PF4 and b-TG concentrations within platelets are similar and
upon platelet activation they are released in similar quantities
[22],[23]. Because PF4 clearance from plasma is much faster than
b-TG clearance (t K for PF4 is several minutes and for b-
TG.100 minutes) [22],[23] a normal or only slightly elevated PF4
level and high b-TG level suggest in vivo platelet activation,
whereas a high b-TG level in combination with a high PF4 level
suggests in vitro (ex-vivo) platelet activation. All samples were
therefore tested for VEGF, b-TG and PF4 using commercially
available sandwich enzyme–linked immunosorbent assays
(ELISAs) from Roche (Asserachrom b-TG and Asserachrom
PF4; Roche, Mannheim, Germany) and R&D Systems (Quanti-
kine VEGF; R&D Systems, Abingdon, UK).
Recovery of VEGF
To exclude the possibility that PECT or citrate medium affects
the measurement of VEGF levels by ELISA, known concentra-
tions of recombinant human VEGF (standard provided in the
assay kit) were added to serum, PECT plasma and citrate plasma
samples to produce VEGF concentrations of 250, 62.5, 31.2, 7.8
and 3.9 pg/ml. The samples were diluted with assay buffer and
the concentration of VEGF was determined by ELISA.
Statistical analysis
Statistical analysis was performed with the computer program
SPSS version 12.0 (SPSS, Gorinchem, The Netherlands) and with
GraphPad Prism software (GraphPad Prism, San Diego, CA,
USA). VEGF, PF4 and b-TG levels in healthy volunteers and
cancer patients were compared using the Mann-Whitney U-test
(unpaired, non-normally distributed groups). Values are presented
as median and interquartile range [t25–t75].
Results
Plasma and platelet VEGF levels
In the three patient groups, VEGF levels in citrate plasma
(Figure 1A) were significantly higher than in PECT plasma
(Figure 1B). VEGF levels in citrate plasma were significantly
higher in both groups of cancer patients compared to healthy
controls, but in PECT plasma this was only the case for patients
with RCC. The VEGF content of isolated platelets, a well known
reservoir for VEGF, was two-fold higher in both cancer patient
groups than in controls (Table 1 and Figure 1C).
In RCC patients, VEGF levels in PECT plasma were con-
siderably higher than in non-RCC patients, whereas the platelet
VEGF content was not different between these groups. VEGF
levels in citrate plasma, PECT plasma, and platelets in the patients
group are shown in Table 1 and Figure 1. These measurements
were not affected by the type of medium used, as recovery of
VEGF was 100–107% in PECT plasma, 73%–107% in citrate
plasma and 78–100% in serum.
In vitro platelet activation
Due to its low half life in vivo, PF4-levels in blood samples are a
measure of artificial ex vivo platelet activation. In our study, in
both healthy controls and cancer patients PF4 concentrations were
50–100 times higher in standard citrate plasma (collected with
Questions cVEGF in Cancer
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(Table 2). This demonstrates that the degree of artificial ex-vivo
platelet activation is highly dependent on the method of harvest,
and that artificial platelet activation in PECT plasma is low and in
citrate plasma samples is high.
As platelet activation is associated with VEGF release, PECT
plasma VEGF levels probably reflect the circulating levels of
VEGF, while the increased levels of VEGF in citrate plasma are
mostly caused by ex vivo platelet activation. This possibility is
strongly supported by the significant correlation which we
observed between PF4 and VEGF levels in individual citrate
plasma samples (Figure 2).
In PECT plasma, we found two-fold higher PF4 values in
cancer patients compared to healthy controls. This indicates that
Figure 1. VEGF levels in cancer patients and controls. A) VEGF-levels measured in citrate plasma of cancer patients compared to healthy
persons. B) VEGF-levels measured in PECT plasma of cancer patients compared to healthy persons. C) VEGF levels measured in platelets of cancer
patients versus healthy persons. Bars represent the medians.
doi:10.1371/journal.pone.0019873.g001
Table 1. VEGF levels in healthy volunteers and cancer patients.
Characteristics Controls Non-RCC RCC
P value Mann
Whitney
Co. vs. Non-RCC
VEGF–citrate
(pg/ml)
30.8
[23.5–44.3]
37.8
[31.2–52.8]
166
[84–238]
0.03
VEGF–PECT
(pg/ml)
17.4
[15.2–22.2]
21.0
[16.0–31.5]
64
[52–134]
NS (0.15)
VEGF in platelets
(pg/10
6 platelets)
3.4
[2.8–4.4]
6.2
[4.1–7.4]
6.0
[3.8–7.1]
0.001
Controls; healthy volunteers; Non-RCC; non-renal carcinoma patients; RCC; renal cell carcinoma patients. VEGF levels in median [interquartile range].
doi:10.1371/journal.pone.0019873.t001
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However, an increased PF4 concentration in individual platelets of
cancer patients may also have contributed to the increased PF4
concentration in PECT plasma (Figure 3).
A high b-TG level in combination with a low PF4 level in
PECT plasma is an indication of in vivo platelet activation. We
were unable to demonstrate such in vivo platelet activation in our
patients with cancer, as b-TG in PECT plasma did not show an
increase independent of the increase in PF4.
Discussion
Our study demonstrates that ‘true’ circulating levels of VEGF,
as determined by measurements in PECT plasma, are low in the
Table 2. Platelet and platelet activation parameters.
Characteristics Controls Non-RCC
P value Mann
Whitney Co. vs.
Non-RCC
Number of platelets
(10
9/l)
259
[237–278]
278
[225–382]
NS (0.13)
PF4-PECT
(IU/ml)
7.7
[5.6–10.3]
14?2
[11.1–87.5]
0.0002
PF4-citrate
(IU/ml)
523
[298–738]
657
[283–806]
NS (0.81)
PF4-in platelets
(IU/10
6 platelets)
11?3
[9.8–12.5]
15?2
[13.3–17.2]
0.0005
b-TG-PECT
(IU/ml)
37.4
[24.1–46.4]
74?7
[51.4–151.4]
0.0005
b-TG-in platelets
(IU/10
6 platelets)
34.3
[29.6–39.3]
36.9
[30.6–41.4]
NS (0.52)
Controls; healthy volunteers; Non-RCC; non-renal carcinoma patients. VEGF levels in median [interquartile range].
doi:10.1371/journal.pone.0019873.t002
Figure 2. Correlation between VEGF and PF4 in citrate plasma in cancer patients and controls. VEGF and PF4 measured in citrate plasma
correlated significantly (r=0.457, p=0.008).
doi:10.1371/journal.pone.0019873.g002
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differ significantly from circulating VEGF levels in controls. The
elevated VEGF levels in citrate plasma samples correlate with PF4,
a marker of ex vivo platelet activation, suggesting that release of
VEGF from platelets during the harvest procedure is responsible
for the VEGF levels in these samples. In addition, we observed
that individual platelets in cancer patients have a two-fold higher
content of VEGF compared to healthy controls. Our findings
show that VEGF levels in blood samples are highly dependent on
the method of collection and platelet VEGF content, and question
the relevance of ‘circulating’ VEGF as a biomarker. Our results do
not rule out that artificially elevated VEGF levels in citrate plasma
samples, as a combined measure of platelet activatibility and
platelet VEGF content, could not be a meaningful surrogate
marker of certain aspects of tumour biology.
A marked increase in plasma VEGF levels has been observed in
various types of cancer employing various collection and
determination methods [11]. A number of studies reported a
correlation between platelet counts and serum VEGF [24,25], and
higher serum VEGF levels per platelet in cancer patients [26,27].
This is in line with our findings and the known function of platelets
as an important reservoir for VEGF. Platelet-derived VEGF may
have an important pathological role in cancer due to thrombin
induced platelet activation and subsequent local release of VEGF,
inducing vascular permeability, endothelial cell activation and
angiogenesis, promoting coagulation and cancer dissemination
[4,28–30].
In the present study, we evaluated two different methods of
plasma collection for VEGF measurement in healthy controls and
cancer patients. The impact of the use of a tourniquet and
collection medium (citrate versus PECT) on VEGF levels was
demonstrated in healthy controls and cancer patients. No
significant differences were detected in PECT VEGF levels
between healthy controls and non-RCC cancer patients.
In RCC patients, PECT VEGF levels were significantly higher
compared to controls, suggesting that in these patients VEGF is
truly elevated inthecirculation. RCCis characterized byhighintra-
tumour VEGF production by homozygous mutations in the von
Hippel-Lindau tumour suppressor gene with consequent unlimited
activity of the hypoxia inducible factor 1a (HIF1a) causing high
VEGF transcription [20–26]. In many of these patients, the other
cells in the body are heterozygous for the VHL mutation. These
genetic aspects may explain why RCC patients have different
circulating VEGF levels than the non-RCC patients studied.
Our findings are in line with the selective success of anti-VEGF
approaches in the treatment of RCC compared to other types of
cancer [31]. Indeed, bevacizumab (Avastin; Genentech, South San
Francisco, CA) an antibody that binds to all isoforms of human
cVEGF [32] produced a significant prolongation of time to disease
progression compared with placebo in patients with RCC [33].
This in contrast with most other tumor types, where bevacizumab
is either not effective or had only significantly antitumor efficacy
when used in combination with chemotherapy rather than as
monotherapy (acting more like chemotherapy-enhancer) [34]. The
straightforward explanation for the clinically relevant activity of
bevacizumab as a monotherapy in RCC might be the specific roles
of defective hypoxic signalling and VEGF overexpression in the
pathogenesis of these tumors.
We observed that in vitro platelet activation during the
collection procedure contributes to higher citrate plasma VEGF
levels. This was demonstrated by the high release of PF4 from
platelets in citrate compared to PECT plasma, and the significant
positive correlation between PF4 and VEGF levels in individual
citrate plasma samples. The two-fold higher levels of PF4 in PECT
plasma in cancer patients compared to controls suggest that also
with the optimal collection method some platelet activation still
occurs, but more importantly this shows that platelets in cancer
patients become more easily activated than platelets from healthy
controls.
In line with other studies we demonstrated that platelet VEGF
content is higher in cancer patients [26,27,35]. In the light of our
findings in PECT plasma, this suggests that ex vivo release of
VEGF by platelets is altered in cancer patients, due to both an
increase in platelet VEGF content as well as to a higher
activatibility of platelets in cancer patients. Higher platelet VEGF
content may originate from increased loading in the bone marrow
or result from a VEGF scavenging function of platelets [6,35,36].
Such a scavenging function would serve to remove excess VEGF,
produced locally in tumour tissues, from the circulation. It is
Figure 3. Scatter plot presentation of the distribution of b-TG
and PF4. A) b-TG and PF4 measured in PECT plasma of cancer patients
compared to controls. B) b-TG and PF4 measured in platelets of cancer
patients compared to controls. Bars represent the medians.
doi:10.1371/journal.pone.0019873.g003
Questions cVEGF in Cancer
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19873remarkable that in both our patient groups the increase in platelet
VEGF content was about two fold compared to controls, despite
the much higher VEGF levels in PECT plasma from RCC
patients. Therefore, if platelets really have a scavenging function
for VEGF, in RCC this scavenging function appears to fail due to
excessively high VEGF production, leading to circulating VEGF.
In addition, in contrast to circulating free VEGF, VEGF content
within platelets may be a meaningful interesting potential
biomarker for VEGF and/or angiogenesis activity in cancer
patients, which needs further studies.
In conclusion, free VEGF levels are low or absent in the
circulation in most cancer patients, with the exception of RCC, a
cancer type with excessive VEGF production due to a specific
genetic defect. Citrate VEGF levels do not reflect actual
circulating VEGF levels but are the result of ex vivo platelet
activation and subsequent VEGF release from platelets which
have an increased VEGF content in cancer patients. Elevated
citrate VEGF levels in cancer patients, which have widely been
used as a biomarker of tumour angiogenesis, are caused by
artefacts and altered platelet behaviour associated with the
systemic disease.
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